Holen Sie sich die Stockscreener-App
0.38
0.03%
0.000100
Handel nachbörslich:
.37
-0.01
-2.63%
Schlusskurs vom Vortag:
$0.3799
Offen:
$0.38
24-Stunden-Volumen:
239.56K
Relative Volume:
0.09
Marktkapitalisierung:
$15.44M
Einnahmen:
$653.40K
Nettoeinkommen (Verlust:
$-20.19M
KGV:
-0.21
EPS:
-1.8091
Netto-Cashflow:
$-11.11M
1W Leistung:
-9.29%
1M Leistung:
-2.81%
6M Leistung:
-38.25%
1J Leistung:
-59.55%
1-Tages-Spanne:
$0.3629
$0.38
1-Wochen-Bereich:
$0.3606
$0.425
52-Wochen-Spanne:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Firmenname
Scienture Holdings Inc
Sektor
Branche
Telefon
(800) 261 0281
Adresse
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.38 | 15.44M | 653.40K | -20.19M | -11.11M | -1.8091 |
HITI
High Tide Inc
|
2.38 | 203.92M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
1.82 | 38.03M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
0.1003 | 13.62M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
4.29 | 11.03M | 23.34M | -101.27M | -11.74M | -1.2919 |
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Scienture (SCNX) Secures Patent for Rezenopy Nasal Spray - GuruFocus
Scienture Secures US Patent Protection for Rezenopy Through 2041 - marketscreener.com
Scienture receives patent for naloxone nasal spray until 2041 By Investing.com - Investing.com South Africa
Scienture receives patent for naloxone nasal spray until 2041 - Investing.com
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 - The Manila Times
New high-dose naloxone nasal spray wins U.S. patent to 2041 - Stock Titan
Scienture Holdings, Inc. (SCNX) 8-K Filing: Director Changes and Company Details for May 2026 - Minichart
Scienture Holdings Announces CFO Resignation, Names Interim Successor - TipRanks
ScientureEric Sherb resigns as CFO effective May 26, 2026 - marketscreener.com
Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026 - marketscreener.com
SCNX Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absenceProfit Inflection Point - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Revenue AbsenceEarnings Preview - The Legal Advocate
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64% Narrows Loss Amid Strategic Progress - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Lack of RevenueNet Income Trends - Newser
Scienture Holdings Reports 449% Revenue Growth and 95.6% Gross Margin Expansion in Q1 2026, Driven by Arbli and REZENOPY Launches - Minichart
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise - Newser
Scienture Holdings (SCNX) Faces Selling Pressure Near Key Support LevelViral Trade Signals - Newser
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline and Operational ProgressViral Trade Signals - Newser
Trxade Health announces name change to Scienture Holdings - Intellectia AI
MEDS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million - Intellectia AI
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. - Intellectia AI
MEDS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
MEDS News & Events - Intellectia AI
Scienture Holdings (SCNX) Q1 2026 Earnings Surprise: EPS $-0.08, Up SignificantViral Trade Signals - Newser
Scienture Holdings Releases Q1 2026 Financial Results - AlphaStreet
Scienture Holdings, Inc. released its financial results and business progress for the first quarter of 2026. - Bitget
Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady - TradingView
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion - The Manila Times
SCIENTURE發佈2026年第一季度財務業績及業務更新，顯著的收入增長和毛利率提升成爲亮點。 - Moomoo
Scienture Holdings Secures $11.4 Million Structured Financing Deal - TipRanks
Scienture Holdings (SCNX) Q4 2025 Earnings: EPS $-0.11 Beats EstimatesTrading Community Hub - Newser
Scienture Holdings Inc (FRA:4E4) Stock Price, Trades & News - GuruFocus
Scienture Holdings: Q1 Earnings Snapshot - marketscreener.com
Scienture Holdings Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Number of shareholders of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
TradingKey - TradingKey
Scienture (SCNX) Secures Patent for Innovative Losartan Suspensi - GuruFocus
Scienture secures $11M debt financing for product launches By Investing.com - Investing.com South Africa
Scienture secures $11M debt financing for product launches - Investing.com UK
Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline - marketscreener.com
Scienture secures $11 million in non-dilutive debt financing - Investing.com
Finanzdaten der Scienture Holdings Inc-Aktie (SCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):